SCHEMBL7697152

SCHEMBL7697152

CNC(=O)C(O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP3 P08254 18/20 0.39
▸ MMP1 P03956 17/20 0.39
▸ MMP9 P14780 10/20 0.39
▸ MMP2 P08253 13/20 0.36
▸ MMP7 P09237 5/20 0.36
▸ MMP8 P22894 3/20 0.36
▸ MMP13 P45452 2/20 0.36
▸ MMP14 P50281 2/20 0.36
▸ ADAM17 P78536 2/20 0.36
▸ MMP20 O60882 1/20 0.36
▸ ADAMTS4 O75173 1/20 0.36
▸ TNF P01375 1/20 0.36
▸ MMP10 P09238 1/20 0.36
▸ MMP12 P39900 1/20 0.36
▸ MMP15 P51511 1/20 0.36
▸ MMP16 P51512 1/20 0.36
▸ MMP25 Q9NPA2 1/20 0.36
▸ MMP26 Q9NRE1 1/20 0.36
▸ ADAMTS5 Q9UNA0 1/20 0.36
▸ MMP24 Q9Y5R2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7697149 1.00 MMP3 (0.39) MMP3MMP1MMP9MMP2MMP7
SCHEMBL7698949 1.00 MMP3 (0.39) MMP3MMP1MMP9MMP2MMP7
SCHEMBL27410744 0.81 MMP3 (0.34) MMP3MMP1MMP9MMP2MMP7
SCHEMBL23371280 0.78 HDAC7 (0.37) MMP3MMP1MMP9MMP2MMP7
SCHEMBL9962280 0.78 POLB (0.39) MMP3MMP2
SCHEMBL26665913 0.76 MAPT (0.32) MMP3MMP1MMP9
SCHEMBL28976649 0.76 PTGS1 (0.31) —
SCHEMBL14602776 0.75 PTGS1 (0.58) MMP3MMP1MMP9MMP2MMP7
SCHEMBL10051718 0.75 PTGS1 (0.58) MMP3MMP1MMP9MMP2MMP7
SCHEMBL19845930 0.74 MMP1 (0.36) MMP3MMP1MMP9MMP2MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2023-02-16 — — US disclosed
US-6348612-B1 FORM COMPLEXES USED AS CATALYSTS FOR ENANTIOSELECTIVE REACTIONS SUCH AS ASYMMETRIC HYDROGENATIONS, ENANTIOSELECTIVE HYDROGEN DISPLACEMENTS, ALLYLIC SUBSTITUTION REACTIONS ROCHE VITAMINS INC. 2002-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK MMP3 3934/4885MMP1 4170/4885MMP9 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback